WO1999051600A1 - AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES - Google Patents
AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES Download PDFInfo
- Publication number
- WO1999051600A1 WO1999051600A1 PCT/US1999/007254 US9907254W WO9951600A1 WO 1999051600 A1 WO1999051600 A1 WO 1999051600A1 US 9907254 W US9907254 W US 9907254W WO 9951600 A1 WO9951600 A1 WO 9951600A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- indole
- trimethylphenyl
- amino
- pyridino
- Prior art date
Links
- 0 Cc(c(N(*)*)c(c(cccc1)c1[n]1[Al]=C)c1n1)c1I Chemical compound Cc(c(N(*)*)c(c(cccc1)c1[n]1[Al]=C)c1n1)c1I 0.000 description 2
- LHCUEDZOSIWWRC-UHFFFAOYSA-N Cc(c(Cl)c(c(cccc1)c1[n]1[AlH2])c1n1)c1I Chemical compound Cc(c(Cl)c(c(cccc1)c1[n]1[AlH2])c1n1)c1I LHCUEDZOSIWWRC-UHFFFAOYSA-N 0.000 description 1
- KTBYKSSVRMJMDK-UHFFFAOYSA-N Cc(cc1C)cc(C)c1-[n]1c2nc(C)cc(N(CC3CC3)Cc3ncccc3)c2c2c1cccc2 Chemical compound Cc(cc1C)cc(C)c1-[n]1c2nc(C)cc(N(CC3CC3)Cc3ncccc3)c2c2c1cccc2 KTBYKSSVRMJMDK-UHFFFAOYSA-N 0.000 description 1
- OIWUPVUWZHGZTL-UHFFFAOYSA-N Cc(cc1C)cc(C)c1-[n]1c2nc(C)cc(N(CCN3CCCC3)CC3CC3)c2c2c1cccc2 Chemical compound Cc(cc1C)cc(C)c1-[n]1c2nc(C)cc(N(CCN3CCCC3)CC3CC3)c2c2c1cccc2 OIWUPVUWZHGZTL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to aminoalkyl substituted 9H-pyridino [2, 3-b] indole and 9H-pyrimidino [4 , 5-b] indole derivatives which selectively bind to corticotropin-releasing factor (CRF]_) receptors and to mammalian neuropeptide Y (NPY ] _) receptors. It further relates to pharmaceutical compositions containing such compounds and the use of such compounds in treating physiological disorders induced or facilitated by CRF or those associated with an excess of neuropeptide Y.
- CRF corticotropin-releasing factor
- Corticotropin releasing factor (herein referred to a ⁇ CRF) , a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland [J. Rivier et al . , Proc . Na t . Acad . Sci . (USA) 80:4851 (1983); . Vale et al . , Science 213:1394 (1981)].
- POMC proopiomelanocortin
- CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders.
- CRF cerebral spinal fluid
- CRF produces anxiogenic effects in animals and interactions between benzodiazepine /
- CRF cardiovascular or heart-related diseases such as hypertension, tachycardia and congestive heart failure, stroke and osteoporosis.
- CRF has also been implicated in premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus and colonic hypersensitivity associated with psychopathological disturbance and stress.
- Neuropeptide Y a peptide first isolated in 1982, is widely distributed in the central and peripheral neurons and is responsible for a multitude of biological effects in the brain and the periphery.
- Various animal studies have shown that activation of neuropeptide NPYi receptors is related to vasoconstriction, Wahlestedt et al . , Regul . Peptides, 13_: 307- 318 (1986), McCauley and Westfall, J. Pharmacol . Exp . Ther. 261: 863-868 (1992), and Grundemar et al . , Br. J. Pharmacol .
- This invention provides novel compounds of Formula I which interact with CRF ⁇ receptors and NPY ⁇ receptors. It further relates to the use of such compounds, pharmaceutical compositions comprising these compounds, and methods useful for the treatment of psychiatric and affective disorders and neurological diseases, including major depression, headaches, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy, as well as treatment of immunological, cardiovascular or heart-related diseases, hypertension, feeding disorders, diabetes, dislipidemia, colonic hypersensitivity associated with psychopathological disturbance, and stress. It further relates to the use of such compounds in treating physiological disorders induced or facilitated by CRF or those associated with an excess of neuropeptide Y.
- this invention provides aminoalkyl substituted 9H-pyridino [2 , 3- b] indole and 9H-pyrimidino [4 , 5-b] indole derivatives of Formula
- CRF ⁇ mammalian neuropeptide Y receptors and/or to mammalian neuropeptide Y (NPY ] _) receptors.
- Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, carboxamido, N-lower alkyl carboxamido, N,N-lower dialkyl carboxamido, Ci-C ⁇ alkyl, Ci-C ⁇ alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;
- R is hydrogen, halogen, trifluoromethyl , C ⁇ -C6 alkyl, or (C ⁇
- 3 3 W is N or C-R where R is hydrogen or C ⁇ -C6 alkyl
- V and V are CH2 , CO, CS, SO2 or CH(C_-C6 alkyl), with
- Y and Y independently represent a bond or C]_-C6 alkylene
- A is NR R wherein R and R are independently hydrogen, a lower alkyl group which optionally forms
- R and R cannot both be alkanoyl or alkylsulfonyl
- N 1 wherein e and f are independently 1, 2 or 3 and the sum of e and f is at least 3;
- R is hydrogen or C ⁇ Cg alkyl
- R is hydrogen or C ⁇ -C6 alkyl; C ⁇ -C ⁇ arylalkyl or C -C6 heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substitu
- G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -C6 alkyl
- heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-,
- 2- or 5-tetrazolyl each of which is optionally mono- or disubstituted with halogen, trifluoromethyl , amino, C ⁇ -C6 alkyl, C ⁇ -C6 alkoxy, with the proviso that tetrazolyl can have at most one substituent ;
- Z is carbon or nitrogen; where when Z 2 is CH, n is 0, 1, 2 or 3 and p is 1, 2, or 3,
- R is carboxamido, or (Crj-C6 alkylene) -G -R
- G is NH, NH(C ⁇ -C6 alkyl) and R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl , and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent
- N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl , each of which is optionally substituted with amino, trifluoromethyl, carboxamido, or (C ⁇ -C6
- R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl, 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl
- the compounds of Formula I are antagonists at the CRFx receptor and are useful in the diagnosis and treatment of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.
- stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.
- psychiatric and affective disorders and neurological diseases including major depression, headaches, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy, as well as treatment of immunological, cardiovascular or heart - related diseases, hypertension, feeding disorders, diabetes, dislipidemia, colonic hypersensitivity associated with psychopathological disturbance, and stress.
- Such methods involve administration to a mammal of an effective amount of a compound of the invention.
- the compounds of Formula I are also neuropeptide Y ] _ receptor antagonists, and, therefore, are also of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of neuropeptide Y.
- the compounds of Formula I have different chemical structures which affect their selectivity towards either the CRFx or the
- NPYx receptors NPYx receptors
- Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, carboxamido, N-lower alkyl carboxamido, N,N-lower dialkyl carboxamido, C ⁇ -C6 alkyl, C ⁇ -C6 alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;
- R is hydrogen, halogen, trifluoromethyl, C ⁇ -Cg alkyl, or (C ⁇
- W is N or C-R where R is hydrogen or C ⁇ -C6 alkyl
- V and V are CH2 , CO, CS, SO2 or CH(C ⁇ -C6 alkyl), with
- Y and Y independently represent a bond or C ⁇ -C ⁇ alkylene
- R and R are independently hydrogen, a lower alkyl group which optionally forms
- heterocycloalkyl group with Y C ⁇ -C6 arylalkyl or C ⁇ -Cg heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl , 1- , 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl or hetero
- R and R cannot both be alkanoyl or alkylsulfonyl
- N 1 wherein e and f are independently 1, 2 or 3 and the sum of e and f is at least 3;
- R is hydrogen or C ⁇ C g alkyl
- C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl where aryl is phenyl , and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl or heterocycloalkyl ring;
- G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -C6 alkyl
- heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-,
- Z is C ⁇ -C6 alkyl
- R is carboxamido, or (C0-C6 alkylene) -G -R
- G is NH, NH(C ⁇ -C6 alkyl) and R is hydrogen, C_,_-C6 alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl , and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent
- N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with amino, trifluoromethyl, carboxamido, or (C ⁇ -C6
- R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl , 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloal
- ⁇ 16- Preferred compounds of Formula I include those of Formula
- each R a is C ⁇ Cg alkyl;
- R b is hydrogen or methyl;
- R- L is C ⁇ Cg alkyl;
- R s is Ci-Cg alkyl, (C 3 -C 5 ) cycloalkyl (C 1 -C 3 ) alkyl, (C 1 -C 3 ) alkoxy (C - C 3 ) alkyl, or (C 3 -C 5 ) cycloalkyl ;
- t is 1, 2 or 3;
- R x is hydrogen, C ⁇ Cg alkyl, phenyl (C ⁇ Cg) alkyl where phenyl is optionally mono- or disubstituted independently with Ci-C 6 alkyl, C ⁇ Cg alkoxy, halogen, or hydroxy; and R y is hydrogen, C ⁇ -C 6 alkyl, (C 3 -C 6 ) cycloalkyl ; or
- NR x R y represents pyrrolidinyl, N- (Ci-C 6 ) alkylpyrrolidin-2-yl , piperidinyl, morpholinyl, or N- (C ⁇ -C 6 ) alkylpiperazinyl .
- Preferred compounds of Formula IA include those where R s is Ci-Cg alkyl or cyclopropylmethyl. Other preferred compounds of Formula IA include those where R s is cyclopropyl (Ci-C 3 ) alkyl . Still other preferred compounds of Formula IA include those where R x and R y independently represent hydrogen or Ci-C 2 alkyl. More preferred compounds of IA include those where R s is cyclopropyl (C 1 -C 3 ) alkyl, R x and R y independently represent hydrogen or C x -C 2 alkyl; and each R a is methyl. Particularly preferred compounds of IA are those W is nitrogen.
- each R a is C 1 -C 6 alkyl ; Ri is Ci-Cg alkyl ; R s is Ci-Cg alkyl , cyclopropyl (Ci-C 3 ) alkyl or (Ci ⁇ C 3 ) alkoxy ( C x -
- R x is hydrogen, Ci-C 6 alkyl , phenyl (C ⁇ Cg) alkyl where phenyl is optionally mono- or disubstituted independently with C ⁇ -C 6 alkyl , Ci-C 6 alkoxy, halogen, or hydroxy; and R y is hydrogen, Ci-C 3 alkyl , (C 3 -C 6 ) cycloalkyl ; or
- NR x R y represents pyrrolidinyl , N- (Ci-C 3 ) alkylpyrrolidin-2 -yl , piperidinyl , morpholinyl , or N- (C ⁇ Cg) alkylpiperazinyl .
- Preferred compounds of Formula IB include those where R s is Ci-Cg alkyl or cyclopropylmethyl. Other preferred compounds of Formula IB include those where R s is cyclopropyl (Ci-C 3 ) alkyl . Yet other preferred compounds of Formula IB include those where t is 1 and R x and R y independently represent hydrogen or C ⁇ -C 2 alkyl . More preferred compounds of Formula IB include those where R s is cyclopropyl (Ci-C 3 ) alkyl , t is 1 and R x and R y independently represent hydrogen or Ci-C 2 alkyl.
- Particularly preferred compounds of IB are those where each R a is methyl, R s is cyclopropyl (Ci-C 3 ) alkyl , t is 1 and R x and R y independently represent hydrogen or Ci-C 2 alkyl.
- Highly preferred compounds of Formula IB are those where W is nitrogen.
- Other preferred compounds of Formula I include those of Formula IC:
- each R a is C ⁇ -C 6 alkyl
- Ri Ci-Cg alkyl ; t is 1 or 2 ;
- Preferred compounds of Formula IC include those wherein R 1 is Ci-C 2 alkyl and W is nitrogen. Other preferred compounds of IC are those where each R a is methyl and W is nitrogen.
- each R a independently represents Ci.C 6 alkyl
- R is hydrogen, halogen, trifluoromethyl , C -C6 alkyl, or (C ⁇
- V and V are CH2 , CO, CS, SO2 or CH(C ⁇ -C6 alkyl), with
- Y and Y independently represent a bond or C ⁇ -C6 alkylene
- 1 4 5 , 4 5 A is NR R wherein R and R are independently hydrogen, a lower alkyl group which optionally forms
- C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1- , 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents
- -20- can together form a 5-7 fused cycloalkyl or heterocycloalkyl ring; lower alkanoyl, lower alkylsulfonyl, with the proviso
- R and R cannot both be alkanoyl or alkylsulfonyl
- N 1 wherein e and f are independently 1, 2 or 3 and the sum of e and f is at least 3;
- R is hydrogen or Ci-C 6 alkyl
- C ⁇ -C6 arylalkyl or C ⁇ -C ⁇ heteroarylalkyl where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, lower
- G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -C6 alkyl
- heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono- or disubstituted with halogen, trifluoromethyl , amino, C ⁇ -C6 alkyl, C -C6 alkoxy, with the proviso that tetrazolyl can have at most one substituent ;
- Z is C ⁇ -C6 alkyl
- V , Y and A are as defined above;
- Z is carbon or nitrogen
- R is carboxamido, or (C0-C6 alkylene) -G -R
- G is NH, NH(C ⁇ -C6 alkyl) and R is hydrogen, C ⁇ -C6 alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl s phenyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substitu
- N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with amino, trifluoromethyl , carboxamido, or (C ⁇ -C6
- R is hydrogen, C ⁇ -C6 alkyl, C ⁇ -C ⁇
- aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl or heterocycloalkyl ring.
- Preferred compounds of Formula II are those where V 1 and
- V 2 represent methylene; Y 1 is a bond; A 1 represents pyrrolidinyl, morpholinyl; piperazinyl, mono- or di-Ci-C 6 alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5-oxazolyl, 2-,
- Y 2 represents a bond or methylene; and A 2 represents C ⁇ C g alkyl or Ci-C 8 alkoxymethyl .
- each R a independently represents C ⁇ C g alkyl
- R is hydrogen, halogen, trifluoromethyl , C ⁇ -C6 alkyl, or (C ⁇
- V and V are CH2, CO, CS, SO2 or CH(C ⁇ -C6 alkyl), with
- Y and Y independently represent a bond or C -C ⁇ alkylene
- A is NR R wherein R and R are independently hydrogen, a lower alkyl group which optionally forms
- heterocycloalkyl group with Y C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1- , 3- or 4-pyrazolyl, 1-, 3- or 4-
- R and R cannot both be alkanoyl or alkylsulfonyl
- R is hydrogen or C ⁇ C g alkyl
- CONH2 CO[N(C ⁇ -C6 alkyl )R ] wherein R is hydrogen or C ⁇ -C6 alkyl; C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4-
- A is hydrogen, C ⁇ -Cg alkyl, (C ⁇ -Cg alkylene) -G -R
- G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -Cg alkyl
- heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4 -imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-,
- 2- or 5-tetrazolyl each of which is optionally mono- or disubstituted with halogen, trifluoromethyl , amino, C ⁇ -Cg alkyl, C ⁇ -Cg alkoxy, with the proviso that tetrazolyl can have at most one substituent ;
- Z is C ⁇ -Cg alkyl
- V , Y and A are as defined above;
- Z is carbon or nitrogen; where when Z 2 is CH, n is 0, 1, 2 or 3 - and p is 1, 2, or 3,
- R is carboxamido, or (Cn-Cg alkylene) -G -R
- G is NH, NH(C ⁇ -Cg alkyl) and R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -Cg arylalkyl or C ⁇ -Cg heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4 -imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5 -thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4 -triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl , each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the provis
- N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with amino, trifluoromethyl, carboxamido, or (C ⁇ -Cg
- R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -Cg arylalkyl or C ⁇ -Cg heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl, 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4 -pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl,
- Preferred compounds of Formula III are those where V 1 and V 2 represent methylene; Y 1 is a bond; A 1 represents pyrrolidinyl, morpholinyl; piperazinyl, mono- or di-Ci-C 6 alkyl, C ⁇ -Cg arylalkyl or C ⁇ -Cg heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4 -pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4 - imidazolyl , 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl , each of
- Preferred compounds of the invention include: 4- (N- (2-N' ,N' -Dimethylaminoethyl) -N-ethyl) amino-2 -methyl - 9- (4-bromo-2 , 6-dimethylphenyl) -9H-pyrimidino [4 , 5-b] indole
- the compounds of Formula I may contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms.
- These compounds can be, for example, racemates or optically active forms.
- the single enantiomers, i.e., optically active forms can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such
- Representative compounds of the present invention include, but are not limited to the compounds in Table I and their pharmaceutically acceptable acid addition salts.
- the free base can be obtained by basifying a solution of the acid salt.
- an addition salt, particularly a pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds .
- Non-toxic pharmaceutical salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH 2 )n-COOH where n is 0-4, and the like.
- acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH 2 )n-COOH where n is 0-4, and the like.
- the present invention also encompasses the acylated prodrugs of the compounds of Formula I.
- acylated prodrugs of the compounds of Formula I Those skilled in the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula I .
- alkyl straight or branched chain alkyl groups having 1-6 carbon atoms optionally forming a 3 to 6 atoms carbocycle, such as, for example, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclopropylmethyl, n-butyl, sec-butyl, tert-butyl, cyclobutyl, pentyl, 2-pentyl, i'sopentyl, neopentyl,
- Co-Cg alkylene is meant a direct bond or a C ⁇ -Cg alkylene group, optionally forming a 3 to 6 atoms carbocycle, such as methylene, ethylidene, propylidene, butylidene, pentylidene, cyclopentylidene, hexylidene, cyclohexylidene.
- alkoxy straight or branched chain alkoxy groups having 1-6 carbon atoms optionally forming a 3 to 6 atoms carbocycle, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, cyclopropylmethoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, cyclopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, cyclohexoxy.
- alkanoyl straight or branched chain alkanoyl groups having 1-6 carbon atoms optionally forming a 3 to 6 atom carbocycle, such as, for example, acetyl, propionyl, isopropionyl, cyclopropionyl, butanoyl, pentanoyl, cyclopentanoyl, hexanoyl, cyclhexanoyl .
- the " ⁇ -position" of the alkanoyl groups herein is the terminal carbon atom.
- CONH represents an amide functional group, i.e., O
- heterocycle or “heterocycloalkyl” means a monocyclic or bicyclic hydrocarbon group which in which one or more of the ring carbon atoms has been replaced with a heteroatom, e.g., oxygen, sulfur or nitrogen. Such groups preferably have 4 to 10 carbon atoms and 1 to 4 heteroatoms .
- halogen in the present invention is meant fluorine, bromine, chlorine, and iodine.
- the compounds of general Formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier.
- One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.
- compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an i-nert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an i-nert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters
- aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachid oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending age-.c and one or more preservatives.
- a dispersing or wetting agent suspending age-.c and one or more preservatives.
- Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachid oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation
- emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
- Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono-or diglycerides .
- fatty acids such as oleic acid find use in the preparation of injectables.
- the compounds of general Formula I may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- Compounds of general Formula I may be administered parenterally in a sterile medium.
- the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- adjuvants such as
- Dosage levels of the order of from about 0. l ⁇ mg to about 140Umg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5Umg to about 7Ug per patient per day) .
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- Dosage unit forms will generally contain between from about l ⁇ mg to about 500Umg of an active ingredient.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
- THF refers to tetrahydrofuran.
- LDA refers to lithium diisopropylamide and DDQ refers to 2 , 3-dichloro-5 , 6-
- Example 1 A. 2 -Amino-4 ,5,6, 7 -tetrahydro-1 -phenyl -lH-indole-3- carbonitrile
- Example IA To the product of Example IA (535 g) dissolved in dichloroethane (4 L) are added 2-methoxypropene (550 mL) and p- toluenesulfonic acid monohydrate (3.6 g) . The mixture is refluxed for 1 hour then the solvent is removed by distillation. The residue is dissolved in THF (3 L) and cooled to 0°C. To this solution, under an atmosphere of nitrogen gas, is added LDA (2.0M, 1.2 L) at a rate to keep the reaction's internal temperature below 10°C. After 3 hours the reaction is neutralized with aqueous HCl. The aqueous layer is extracted with ethyl acetate and combined with the THF layer.
- 2-methoxypropene 550 mL
- p- toluenesulfonic acid monohydrate 3.6 g
- the mixture is refluxed for 1 hour then the solvent is removed by distillation.
- the residue is dissolved in THF (3 L) and
- Example IB The product of Example IB (600 g) is dissolved in decahydronaphthalene (4 L) and heated to distill off low boiling impurities that are present. The solution is cooled to ambient temperature and charged with 10% Palladium on Carbon
- a steel bomb containing the product from Example IE (61 g) , pyrrolidine (60 mL) and N-methylpyrrolidinone (250 mL) is sealed and heated to 120°C for 5 hours.
- the mixture is poured into water and extracted with ethyl acetate.
- the organic layer is washed with water, dried over sodium sulfate, filtered and concentrated.
- the product is purified by flash chromatography. First 100% ethyl acetate is used to elute impurities followed by 10% methanol in dichloromethane to elute the desired product. Obtain 60 g of compound that crystallizes on standing.
- the sulfate salt of the amine is formed by adding concentrated sulfuric acid (2.44 mL) to amine (21.4 g) dissolved in ethanol (50 mL) . Isopropanol (200 mL) is added to the ethanol solution at reflux. Crystals of sulfate that form on cooling are collected by filtration and washed with cold isopropanol: MS (free base) 467 (M+H).
- Example 2 The following compounds are prepared essentially according to the procedures set forth above in Example 1. a) 4- (N- (2-N' ,N' -Dimethylaminoethyl) -N-propyl) amino-2- methyl-9- (2,4, 6 -trimethylphenyl) -9H-pyridino [2, 3-b] indole: MS 429 (M+H) . (Compound 2)
- Example 9 The following compounds are prepared essentially according to the procedure set forth in Example 8.
- Example 11 The following compounds are prepared essentially according to the procedure set forth in Example 10. a) 4- (N- (2-Pyrrolidinoethyl) -N- cyclopropyloxomethyl) amino-2 -methyl -9- (2,4, 6-trimethylphenyl) - 9H-pyridino [2,3-b] indole: MS 481 (M+H). (Compound 69)
- Example 13 The following compounds are prepared essentially according to the procedure of Example 12. a) 4- (N- (2 -N' ,N' -Dimethylamino-2 -oxoethyl ) -N-2 - methoxyethyl) amino-2 -methyl -9- (2,4, 6 -trimethylphenyl) -9H- pyridino [2, 3-b] indole: MS 459 (M+H). (Compound 72)
- Example 16 The following compounds are prepared essentially according to the procedures set forth above in Example 15.
- Example 17 A. 2 -Amino- 1 -phenyl -1H- indole-3 -carbonitrile
- Example 12B The compound from Example 12B (2.2 g) is refluxed in phosphoryl chloride (30 mL) for 3 hours. The excess phosphoryl chloride is removed under reduced pressure and the residue is partitioned between aqueous potassium carbonate and dichloromethane. The aqueous is extracted with more dichloromethane. The combined extracts are dried over sodium sulfate, filtered and concentrated to give a tan colored solid: MS 336 (M+H) .
- Example 18 The following compounds are prepared essentially according to the procedure of Example 17.
- Example 19 The pharmaceutical utility of compounds of this invention is indicated by the following assays for human CRF1 and NPYI receptor activity. Assay for CRF Receptor Binding Activity
- CRF receptor binding is performed using a modified version of the assay described by Grigoriadis and De Souza (Methods in Neurosci ences, Vol. 5, 1991) .
- Membrane pellets containing CRF receptors are re-suspended in 50mM Tris buffer pH 7.7 containing 10 mM MgCl2 and 2 mM EDTA and centrifuged for 10 minutes at 48000g. Membranes are washed again and brought to a
- binding buffer Tris buffer above with 0.1 % BSA, 15 mM bacitracin and 0.01 mg/mL aprotinin
- 100 mL of the membrane preparation is added to 96 well microtube plates containing 100 mL of 1 25I-CRF (SA 2200 Ci/mmol, final concentration of 100 pM) and 50 mL of drug. Binding is carried out at room temperature for 2 hours. Plates are then harvested on a Brandel 96 well cell harvester and filters are counted for gamma emissions on a Wallac 1205 Betaplate liquid scintillation counter. Non specific binding is defined by 1 mM cold CRF.
- I 50 values are calculated with the non-linear curve fitting program RS/1 (BBN Software Products Corp., Cambridge, MA) .
- the binding affinity for the compounds of Formula I expressed as IC50 value generally ranges from about 0.5 nanomolar to about 10 micromolar.
- the binding activity of the compounds of formula I to the human CRF receptor can be measured as follows : Assay for Human CRF Receptor Binding Activity in IMR32 cells
- IMR-32 human neuroblastoma cells are grown to 80% confluence in EMEM containing Earle's Balanced Salts and 2 mM 1 -glutamine with 10% FBS, 25 mM HEPES, 1 mM Sodium Pyruvate, and nonessential amino acids. At this time, flasks of cells are treated with 2.5 ⁇ M 5-bromo-2 ' -deoxyuridine (Br-dU) for 10 days. Media is changed every 3-4 days across the 10 day period. Cells are harvested using No-Zyme (JRH Biosciences) and rinsed with PBS. For membrane preparation, cells are homogenized in wash buffer (50 mM Tris HCl, 10 mM
- -81- is performed using assay buffer (50 mM Tris HCl, 10 mM MgCl 2 , 2 mM EGTA, pH 7.4 , 0.1% BSA, 0.1 mM bacitrac (22.0mg/l00 mL) ) , 150 ⁇ g protein/tube, and [ 125 I] Sauvagine (NEN; 100 pM for competition analysis and 10 pM-1 nM for saturation analysis) to yield a final volume of 200 ⁇ L.
- Nonspecific binding is defined using 2 ⁇ M r/h CRF or 9-41 alpha-helical CRF. Cells are incubated for 2 hours at room temperature.
- the assay is terminated by rapid vacuum filtration (Tomtec: Deepwell 3) through GFC filters presoaked in 1% PEI using ice-cold 50 mM Tris HCl and dry thoroughly by air.
- Specific Binding 70-80%; Kd (nM) : 0.30 nM; Bmax (fmole/mg protein): 40-50.
- IC50 values are calculated with the non-linear curve fitting program RS/l (BBN Software Products Corp., Cambridge, MA) .
- the binding affinities for the compounds of Formula I towards the 0RF ⁇ receptor are expressed as IC50 values and are less than 10 micromolar.
- Compounds are assayed for activity using the following method: Baculovirus-infected Sf9 cells expressing recombinant human NPY Yl receptors are harvested at 42-48 hours at which time batches of 500 mL of cell suspension are pellete ⁇ by centrifugation.
- Each pellet is re-suspended 30 mL of lysis buffer (10 mM HEPES, 250 mM sucrose, 0.5 ⁇ g/mL leupeptin, 2 ⁇ g/mL Aprotonm, 200 ⁇ M PMSF and 2.5 mM EDTA, pH 7.4 and gently homogenized by 50 strokes using a dounce homogenizer
- the homogenate is centrifuged at 4°C for 10 minutes at 536 x g to pellet the nuclei.
- the supernatant is collected into a fresh tube and centrifuged twice in the same buffer at 48,000 x g for 40 minutes.
- the final pellet is subsequently re-suspe ⁇ e ⁇ 10 L of PBS containing 5 mM EDTA by dounce homogenization and stored m aliquots at -80°C.
- NPY [ 125I] NPY (porcine) for saturation analysis.
- GTP is added at a final concentration of 100 ⁇ M.
- Cold displacers are added at concentrations ranging from 10 - ⁇ 2 M to 10 6 M to yield a final volume of 0.250 mL.
- Nonspecific binding is determined in the presence of 1 ⁇ M NPY (human) and accounts for less than 10% of total binding.
- the reaction is terminated by rapid vacuum filtration. Samples are filtered over presoaked GF/C Whatman filters (1.0% polyethyleneimine for 2 hours) and rinsed 2 times with 5 mL cold binding buffer lacking BSA. Remaining bound radioactivity is measured by gamma counting. To estimate the Bmax, Kd and Ki , the results of binding experiments are analyzed using SigmaPlot software (Jandel) .
- the binding affinities for the compounds of Formula I towards the NPY]_ receptor are expressed as IC50 values and are less than 10 micromolar.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002326606A CA2326606A1 (en) | 1998-04-02 | 1999-04-01 | Aminoalkyl substituted 9h-pyridino[2,3-b]indole and 9h-pyrimidino[4,5-b]indole derivatives:crf1 and npy1 receptors |
JP2000542321A JP2002510688A (en) | 1998-04-02 | 1999-04-01 | Aminoalkyl-substituted 9H-pyridino [2,3-b] indole and 9H-pyrimidino [4,5-b] indole derivatives |
EP99916294A EP1068207A1 (en) | 1998-04-02 | 1999-04-01 | AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
AU34645/99A AU3464599A (en) | 1998-04-02 | 1999-04-01 | Aminoalkyl substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8045198P | 1998-04-02 | 1998-04-02 | |
US60/080,451 | 1998-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999051600A1 true WO1999051600A1 (en) | 1999-10-14 |
Family
ID=22157476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/007254 WO1999051600A1 (en) | 1998-04-02 | 1999-04-01 | AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1068207A1 (en) |
JP (1) | JP2002510688A (en) |
AU (1) | AU3464599A (en) |
CA (1) | CA2326606A1 (en) |
WO (1) | WO1999051600A1 (en) |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066585A1 (en) * | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
EP1097709A2 (en) * | 1999-10-29 | 2001-05-09 | Pfizer Products Inc. | Use of corticotropin releasing factor antagonists for treating syndrome X |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US6967216B2 (en) | 2000-05-05 | 2005-11-22 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
WO2006001511A1 (en) * | 2004-06-25 | 2006-01-05 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists |
US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
US7125906B2 (en) | 2002-04-03 | 2006-10-24 | Astrazeneca Ab | Indole derivatives having anti-angiogenetic activity |
WO2006129826A1 (en) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
WO2007055418A1 (en) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US7408064B2 (en) | 2001-09-11 | 2008-08-05 | Astrazeneca Ab | Carbazole derivatives and their use as NPY5 receptor antagonists |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
US7557111B2 (en) | 2004-01-06 | 2009-07-07 | Taisho Pharmaceutical Co., Ltd. | Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
WO2009119726A1 (en) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
WO2010013595A1 (en) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2332526A2 (en) | 2005-10-21 | 2011-06-15 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8106194B2 (en) | 2004-01-06 | 2012-01-31 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolotriazine derivatives |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US9732083B2 (en) | 2011-03-15 | 2017-08-15 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013676A1 (en) * | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrrolopyrimidines as crf antagonists |
WO1995033750A1 (en) * | 1994-06-08 | 1995-12-14 | Pfizer Inc. | Corticotropin releasing factor antagonists |
WO1996035689A1 (en) * | 1995-05-12 | 1996-11-14 | Neurogen Corporation | Novel deazapurine derivatives; a new class of crf1 specific ligands |
WO1998045295A1 (en) * | 1995-10-13 | 1998-10-15 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel crf1 specific ligands |
-
1999
- 1999-04-01 EP EP99916294A patent/EP1068207A1/en not_active Withdrawn
- 1999-04-01 JP JP2000542321A patent/JP2002510688A/en active Pending
- 1999-04-01 WO PCT/US1999/007254 patent/WO1999051600A1/en not_active Application Discontinuation
- 1999-04-01 CA CA002326606A patent/CA2326606A1/en not_active Abandoned
- 1999-04-01 AU AU34645/99A patent/AU3464599A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013676A1 (en) * | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrrolopyrimidines as crf antagonists |
WO1995033750A1 (en) * | 1994-06-08 | 1995-12-14 | Pfizer Inc. | Corticotropin releasing factor antagonists |
WO1996035689A1 (en) * | 1995-05-12 | 1996-11-14 | Neurogen Corporation | Novel deazapurine derivatives; a new class of crf1 specific ligands |
WO1998045295A1 (en) * | 1995-10-13 | 1998-10-15 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel crf1 specific ligands |
Non-Patent Citations (3)
Title |
---|
C.E. MÜLLER ET AL., JOURNAL OF MEDICINAL CHEMISTRY., vol. 33, 1990, WASHINGTON US, pages 2822 - 2828, XP002106454 * |
C.E. MÜLLER ET AL., JOURNAL OF MEDICINAL CHEMISTRY., vol. 39, 1996, WASHINGTON US, pages 2482 - 2491, XP002106452 * |
K. EGER ET AL., LIEBIGS ANNALEN DER CHEMIE., 1993, WEINHEIM DE, pages 465 - 470, XP002106453 * |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6284766B1 (en) | 1999-04-30 | 2001-09-04 | Neurogen Corporation | 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands |
WO2000066585A1 (en) * | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
EP1097709A2 (en) * | 1999-10-29 | 2001-05-09 | Pfizer Products Inc. | Use of corticotropin releasing factor antagonists for treating syndrome X |
EP1097709A3 (en) * | 1999-10-29 | 2005-12-21 | Pfizer Products Inc. | Use of corticotropin releasing factor antagonists for treating syndrome X |
US6967216B2 (en) | 2000-05-05 | 2005-11-22 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
US7332492B2 (en) | 2000-05-05 | 2008-02-19 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
US7408064B2 (en) | 2001-09-11 | 2008-08-05 | Astrazeneca Ab | Carbazole derivatives and their use as NPY5 receptor antagonists |
US7125906B2 (en) | 2002-04-03 | 2006-10-24 | Astrazeneca Ab | Indole derivatives having anti-angiogenetic activity |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US8106194B2 (en) | 2004-01-06 | 2012-01-31 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolotriazine derivatives |
US7557111B2 (en) | 2004-01-06 | 2009-07-07 | Taisho Pharmaceutical Co., Ltd. | Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
AU2011200450B2 (en) * | 2004-06-25 | 2011-05-26 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists |
EP1953160A1 (en) * | 2004-06-25 | 2008-08-06 | Taisho Pharmaceutical Co., Ltd | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists |
AU2005257496B2 (en) * | 2004-06-25 | 2011-01-06 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists |
US7951811B2 (en) | 2004-06-25 | 2011-05-31 | Taisho Pharmaceutical Co., Ltd. | Pyrrolo[2,3-D]pyrimidine derivatives substituted with a cyclic amino group |
WO2006001511A1 (en) * | 2004-06-25 | 2006-01-05 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists |
EP2286839A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
EP2286837A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and obesity related diseases |
EP2286840A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2286838A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2006129826A1 (en) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
EP2332526A2 (en) | 2005-10-21 | 2011-06-15 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
WO2007055418A1 (en) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
WO2009119726A1 (en) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (en) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US10858360B2 (en) | 2011-03-15 | 2020-12-08 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
US9732083B2 (en) | 2011-03-15 | 2017-08-15 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10513499B2 (en) | 2014-08-29 | 2019-12-24 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
US11254644B2 (en) | 2014-08-29 | 2022-02-22 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
AU3464599A (en) | 1999-10-25 |
JP2002510688A (en) | 2002-04-09 |
EP1068207A1 (en) | 2001-01-17 |
CA2326606A1 (en) | 1999-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1068207A1 (en) | AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES | |
US6436932B1 (en) | Aminoalkyl substituted pyrrolo[3,2-e] pyridine and pyrrolo[2,3-b]pyrimidine derivatives: modulators of CRF1 receptors | |
US7151109B2 (en) | Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | |
US6291473B1 (en) | Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands | |
US6362186B1 (en) | Aminoalkyl substituted 9H-phridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives | |
CA2520900A1 (en) | Pyrrolo[1,2-b]pyridazine compounds and their use as crf1 receptor antagonists | |
US7034023B2 (en) | Pyrrolo[1,2-B]pyridazine compounds and their uses | |
US6472402B1 (en) | Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives | |
CA2523072A1 (en) | Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists | |
US7074791B2 (en) | Pyrrolo[1,2-b]pyridazine compounds and their uses | |
US7056920B2 (en) | Pyrrolo[1,2-B]pyridazine compounds and their uses | |
MXPA00009565A (en) | AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES | |
US20070224636A1 (en) | Pyrrolo[1,2b]pyridazine compounds and their uses | |
US20060166998A1 (en) | Pyrrolo[1,2-B]pyridazine compounds and their uses | |
MXPA00009575A (en) | Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives:modulators of crf1 receptors | |
WO2004092176A1 (en) | Pyrrolo[1,2-b]pyridazine compounds and their uses | |
MXPA00009566A (en) | Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7, 8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives:crf1 specific ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2326606 Country of ref document: CA Ref country code: CA Ref document number: 2326606 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/009565 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 542321 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999916294 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999916294 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999916294 Country of ref document: EP |